Literature DB >> 12243501

Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: patients monitored by absorption profiling.

C M Clase1, K Mahalati, B A Kiberd, J G Lawen, K A West, A D Fraser, P Belitsky.   

Abstract

This study used receiver operating characteristic analysis to investigate the properties of area under the concentration-time curve during the first 4h after cyclosporin-microemulsion dosing (AUC0-4) and cyclosporin (CyA) levels immediately before and at 2 and 3h after dosing (C0, C2 and C3) to predict the risk of biopsy-proven acute rejection (AR) at 6 months. Ninety-eight kidney transplant recipients treated with CyA-microemulsion-based triple therapy immunosuppression were studied on post-transplant days 3, 5, and 7, and at increasing intervals thereafter. The most sensitive and specific predictor of AR was AUC0-4. Of the single time-point measurements, the measurement properties of C2 were closest to those of AUC0-4, and superior to those of C3. The relationship between C0 and subsequent AR was weak and did not reach statistical significance. On day 3, CyA AUC0-4 > or = 4,400 ng.h/mL and C2 > or = 1,700 ng/mL were each associated with a 92% negative predictive value for rejection in the first 6months. Pharmacokinetic measurements on or after day 5, and measurements on day 3 in patients with delayed graft function, were not predictive of AR. Adequate exposure within the first 3days post transplantation may be critically important in preventing subsequent rejection.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12243501     DOI: 10.1034/j.1600-6143.2002.20814.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  18 in total

1.  Combination therapy with diltiazem plus CsA/MMF/Pred or CsA/Aza/Pred triple immunosuppressive regimens for use in clinical kidney transplantation in Northwestern China.

Authors:  Yong Song; Wujun Xue; Puxun Tian; Xiaoming Ding; Xiaoming Pan; Hang Yan; Jun Hou; Xinshun Feng; Heli Xiang; Xiaohui Tian; Gaoping Qin; Xiaohu Fan
Journal:  Eur J Clin Pharmacol       Date:  2011-01-29       Impact factor: 2.953

2.  Modelling ciclosporin double-peak absorption profiles in the early post-transplantation period.

Authors:  Annick Rousseau; Pierre Marquet
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

3.  Effectiveness and nephrotoxicity of a 2-year medium dose of cyclosporine in pediatric patients with steroid-dependent nephrotic syndrome: determination of the need for follow-up kidney biopsy.

Authors:  Yoshiyuki Kuroyanagi; Yoshimitsu Gotoh; Katsuaki Kasahara; China Nagano; Naoya Fujita; Satoshi Yamakawa; Masaki Yamamoto; Asami Takeda; Osamu Uemura
Journal:  Clin Exp Nephrol       Date:  2017-07-11       Impact factor: 2.801

Review 4.  The impact of age on rejection in kidney transplantation.

Authors:  Johan W de Fijter
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

5.  Cyclosporin A in idiopathic chronic fibrosing interstitial pneumonia without idiopathic pulmonary fibrosis.

Authors:  Reoto Takei; Machiko Arita; Fumiaki Tokioka; Hiromasa Tachibana; Hironobu Tokumasu; Tadashi Ishida
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

6.  [Significance of cyclosporin A absorption for effective immunomodulatory therapy after high-risk keratoplasty].

Authors:  N Bailly; I Dunewa; P Schlattmann; P W Rieck
Journal:  Ophthalmologe       Date:  2008-05       Impact factor: 1.059

7.  Effect of genetic polymorphisms of CYP3A5 and MDR1 on cyclosporine concentration during the early stage after renal transplantation in Chinese patients co-treated with diltiazem.

Authors:  Yixi Wang; Changxi Wang; Jiali Li; Xueding Wang; Genglong Zhu; Xiao Chen; Huichang Bi; Min Huang
Journal:  Eur J Clin Pharmacol       Date:  2008-10-21       Impact factor: 2.953

8.  Cyclosporine C2 monitoring for the treatment of frequently relapsing nephrotic syndrome in children: a multicenter randomized phase II trial.

Authors:  Kazumoto Iijima; Mayumi Sako; Mari Saito Oba; Shuichi Ito; Hiroshi Hataya; Ryojiro Tanaka; Yoko Ohwada; Koichi Kamei; Kenji Ishikura; Nahoko Yata; Kandai Nozu; Masataka Honda; Hidefumi Nakamura; Michio Nagata; Yasuo Ohashi; Koichi Nakanishi; Norishige Yoshikawa
Journal:  Clin J Am Soc Nephrol       Date:  2013-11-21       Impact factor: 8.237

9.  ABCB1 polymorphisms may have a minor effect on ciclosporin blood concentrations in myasthenia gravis patients.

Authors:  Ya-tong Zhang; Li-ping Yang; Hong Shao; Ke-xin Li; Chun-hua Sun; Lu-wen Shi
Journal:  Br J Clin Pharmacol       Date:  2008-08       Impact factor: 4.335

10.  A population pharmacokinetic model of ciclosporin applicable for assisting dose management of kidney transplant recipients.

Authors:  Pål Falck; Karsten Midtvedt; Thanh Trúc Vân Lê; Live Storehagen; Hallvard Holdaas; Anders Hartmann; Anders Asberg
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.